<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31698511</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>92</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical endocrinology</Title>
          <ISOAbbreviation>Clin Endocrinol (Oxf)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline may act as a radioprotective agent in Cushing's disease.</ArticleTitle>
        <Pagination>
          <StartPage>55</StartPage>
          <EndPage>62</EndPage>
          <MedlinePgn>55-62</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cen.14123</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT">Conventional fractionated radiotherapy (CRT) achieves control of pathological hypercortisolism in 75%-80% of patients with persistent or recurrent Cushing's disease (CD), over a mean period of 18-24 months. Medical therapy is recommended as bridge therapy while awaiting RT effect.</AbstractText>
          <AbstractText Label="OBJECTIVE">To determine long-term outcome of CRT and its predictors in CD patients.</AbstractText>
          <AbstractText Label="DESIGN, SETTING AND PATIENTS">This is a retrospective case record analysis of 42 patients with CD who received CRT as a treatment modality and had at least 12 months post-RT follow-up. The dose delivered was 45 Gy in 25 fractions over 5 weeks. Demographic details, hormonal evaluation and radiological data were extracted from case records. Dexamethasone suppressed cortisol at cut-off of 1.8 µg/dL was used to define remission or recurrence. Possible predictors for remission and recurrence were analysed.</AbstractText>
          <AbstractText Label="RESULTS">The mean age at the time of CRT administration was 23.7 ± 10.7 (range: 12-48) years. A total of 29 (69%) patients achieved remission 26.5 ± 28.5 (median: 18, range: 3-120) months after RT, while 13 (31%) patients had persistent disease at last follow-up. There were no significant predictors of disease remission after CRT. Six (20.7%) patients had recurrence after a documented initial remission. Recurrence occurred 66.6 ± 25.9 (median: 74; range: 18 to 90) months after documented remission. Recurrence of the disease was exclusively seen in patients who received peri-RT cabergoline. Peri-CRT use of cabergoline was significantly associated with increased recurrence rates (P = .016).</AbstractText>
          <AbstractText Label="CONCLUSION">Use of cabergoline in the peri-CRT period did not affect initial remission after CRT but was associated with increased recurrence after initial remission in CD.</AbstractText>
          <CopyrightInformation>© 2019 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thakkar</LastName>
            <ForeName>Kunal</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lila</LastName>
            <ForeName>Anurag</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarathi</LastName>
            <ForeName>Vijaya</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-0243-0448</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Narayana Medical College, Nellore, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramteke-Jadhav</LastName>
            <ForeName>Swati</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-1251-8918</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goroshi</LastName>
            <ForeName>Manjunath</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-7679-6656</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, JN Medical College and KLES Hospital, Belgaum, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Memon</LastName>
            <ForeName>Saba Samad</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krishnatry</LastName>
            <ForeName>Rahul</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Tejpal</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jalali</LastName>
            <ForeName>Rakesh</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Apollo Proton Cancer Centre, Apollo Hospitals, Chennai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goel</LastName>
            <ForeName>Atul</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Abhidha</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sankhe</LastName>
            <ForeName>Shilpa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patil</LastName>
            <ForeName>Virendra</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bandgar</LastName>
            <ForeName>Tushar</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-6902-4639</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Nalini S</ForeName>
            <Initials>NS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Seth G S Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Endocrinol (Oxf)</MedlineTA>
        <NlmUniqueID>0346653</NlmUniqueID>
        <ISSNLinking>0300-0664</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011837">Radiation-Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047748" MajorTopicYN="N">Pituitary ACTH Hypersecretion</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011837" MajorTopicYN="N">Radiation-Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">conventional/conformal fractionated radiotherapy</Keyword>
        <Keyword MajorTopicYN="Y">ketoconazole</Keyword>
        <Keyword MajorTopicYN="Y">overnight dexamethasone suppression test</Keyword>
        <Keyword MajorTopicYN="Y">recurrence</Keyword>
        <Keyword MajorTopicYN="Y">remission</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31698511</ArticleId>
        <ArticleId IdType="doi">10.1111/cen.14123</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Petersenn S, Beckers A, Ferone D, et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol. 2015;172(6):R227-R239.</Citation>
        </Reference>
        <Reference>
          <Citation>Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.</Citation>
        </Reference>
        <Reference>
          <Citation>Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336(3):172-177.</Citation>
        </Reference>
        <Reference>
          <Citation>Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Enrici RM. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neuro-Oncol. 2007;84(1):79-84.</Citation>
        </Reference>
        <Reference>
          <Citation>Lila A, Gopal R, Acharya S, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010;16(6):968-976.</Citation>
        </Reference>
        <Reference>
          <Citation>Budyal S, Lila AR, Jalali R, et al. Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing’s disease. Pituitary. 2014;17(1):60-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. Endocr Rev. 2015;36(4):385-486.</Citation>
        </Reference>
        <Reference>
          <Citation>Dabrh AM, Singh Ospina NM, Nofal AA, et al. Predictors of biochemical remission and recurrence after surgical and radiation treatments of Cushing disease: a systematic review and meta-analysis. Endocr Pract. 2016;22(4):466-475.</Citation>
        </Reference>
        <Reference>
          <Citation>Castinetti F, Nagai M, Dufour H, et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol. 2007;156(1):91-98.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML. Results of gamma knife surgery for Cushing's disease. J Neurosurg. 2013;119(6):1486-1492.</Citation>
        </Reference>
        <Reference>
          <Citation>Guzzo MF, Carvalho LR, Bronstein MD. Ketoconazole treatment decreases the viability of immortalized pituitary cell lines associated with an increased expression of apoptosis-related genes and cell cycle inhibitors. J Neuroendocrinol. 2015;27(7):616-623.</Citation>
        </Reference>
        <Reference>
          <Citation>Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Sutton ML. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf). 1990;33(4):445-455.</Citation>
        </Reference>
        <Reference>
          <Citation>Murayama MA, Yasuda KE, Minamori YO, Mercado-Asis LB, Yamakita NO, Miura KI. Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation. J Clin Endocrinol Metab. 1992;75(3):935-942.</Citation>
        </Reference>
        <Reference>
          <Citation>Shepard MJ, Mehta GU, Xu Z, et al. Technique of whole-sellar stereotactic radiosurgery for Cushing disease: results from a multicenter, international cohort study. World Neurosurg. 2018;116:e670-e679.</Citation>
        </Reference>
        <Reference>
          <Citation>Booth AK, Gutierrez-Hartmann A. Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol. 2015;846:37-59.</Citation>
        </Reference>
        <Reference>
          <Citation>Zatelli MC, Ambrosio MR, Bondanelli M, Uberti EC. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol. 2007;156(suppl _1):S29-S35.</Citation>
        </Reference>
        <Reference>
          <Citation>Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab. 2000;85(3):1287-1289.</Citation>
        </Reference>
        <Reference>
          <Citation>Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurgery. 2000;93(suppl_3):14-18.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
